Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patient.
Salha Fendri, Pelin Karaca, Evelyne Tiev, Michael Buchfelder, Jean-Daniel Lalau
Index: Ann. Endocrinol. (Paris.) 74(1) , 49-52, (2013)
Full Text: HTML
Abstract
We report on a 30-year-old female acromegalic patient treated with the growth hormone (GH) receptor antagonist pegvisomant at a low dose after the failure of long-acting lanreotide, neurosurgery and radiotherapy treatment to restore IGF-1 levels. The combination treatment was well tolerated and produced a dramatic improvement in the patient's condition (reduction in visual field defects, relief of headache and excessive perspiration), normalization of IGF-I levels and a considerable decrease in tumor size, enabling a dramatic decrease in lanreotide dosage and, ultimately, its withdrawal.Copyright © 2012 Elsevier Masson SAS. All rights reserved.
Related Compounds
Related Articles:
[Drug therapy for acromegaly].
2013-09-29
[Orv. Hetil. 154(39) , 1527-34, (2013)]
2013-09-01
[Pituitary 16(3) , 354-62, (2013)]
Merkel cell carcinoma of the auricle: a treacherous skin tumor.
2012-01-01
[J. Cancer Res. Ther. 8(3) , 460-2, (2012)]
Palliative interventions in patients with peritoneal metastases and malignant bowel obstruction.
2012-12-10
[J. Clin. Oncol. 30(35) , 4290-1, (2012)]
Carcinoid crisis induced by repeated abdominal examination.
2012-03-01
[Intern. Med. J. 42(3) , 342-4, (2012)]